NLRP3 and COVID-19: This raises the questions if (i) patients with NLRP3 inflammasome-associated cytokine release are at higher risk of hypercytokinemia and increased AID activity during or after acute COVID-19; and if (ii) maintenance anti-IL-1 treatment, applied in IL-1-mediated AID to avoid inflammasome activation and cytokine release, also reduces COVID-19-related cytokine dysregulation accounting for mild or asymptomatic COVID-19 disease courses in these patients.